摘要
Abstract
OBJECTIVE: To observed the short-term clinical efficacy and safety of Aidi injection combined with TP chemotherapy for medium and advanced non-small-cell lung cancer (NSCLC). METHODS: 39 patients with medium and advanced NSCLC admitted in our hospital during Mar. 2007—Jun. 2011 were randomized into treatment group (23 cases) and control group (16 cases). Control group was given TP chemotherapy (paclitaxel 175 mg·m-2,i.v.gtt. d1, cisplatin 30 mg·m-2, i.v.gtt., d1~3); treatment group was given Aidi injection (50 mL, i.v. gtt,d1~14) additionally on the basis of treatment for control group. Therapeutic efficacy, clinical profit and toxic reaction were observed after 2 courses of chemotherapy. RESULTS: The effective rate of treatment group was 52.17%, while that of control group was 43.75%, and there was statistical significant difference (P<0.05). The clinical profit of treatment group was improved, compared with control group (KPS score increasing >20 points: treatment group of 60.87% , control group of 43.75%; body weight increasing >7%: treatment group of 56.52%, control group of 37.50%; amount of analgesic agent decreasing 50%: treatment group of 43.48%, control group of 31.25%; pain degree decreasing>50%: treatment group of 47.83%, control group of 37.50%), there was statistical significance in the difference between 2 groups (P<0.05); the toxic reaction of treatment group was relieved, compared with control group (the incidence of gastrointestinal reaction were 30.43% for treatment group and 37.50% for control group; the incidence of leucocytopenia was 17.39% for treatment group and 43.75% for control group; the incidence of thrombocytopenia was 13.04% for treatment group and 31.25% for control group), there was statistical significance in the difference among 2 groups (P<0.05). CONCLUSION: Compared with TP chemotherapy alone, Aidi injection combined with TP chemotherapy can not only improve short-term efficacy and the life qualities of patients, but also reduce the rate of toxicity reaction.
关键词
艾迪注射液/TP化疗方案/非小细胞肺癌/近期疗效/临床收益/毒性反应Key words
Aidi injection/ TP chemotherapy/ Non-small-cell lung cancer/ Short-term efficacy/ Clinical profit/ Toxic reaction分类
医药卫生
